TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31112641
Drug: Midazolam-butorphanol (MB;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam-butorphanol (MB; 3 mg/kg each IM)
Study: 26125538
Drug: Armodafinil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil (up to 150 mg/d for 4 weeks)
Study: 24812897
Drug: Xifeng Zhidong
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xifeng Zhidong Tablet (XZT)
Study: 8629589
Drug: Combined alpha-beta
Normalized name: .alpha.,.beta.'-diglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined alpha-beta blockade (doxazosin 4 mg/day plus metoprolol 6.25 mg, gradually increased to 50 mg twice daily)
Study: 8629589
Drug: Metoprolol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol alone (6.25 mg, gradually increased to 50 mg twice daily)
Study: 2123759
Drug: Pure follicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure follicle stimulating hormone (FSH)
Study: 30184513
Drug: Serum 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25-hydroxyvitamin D levels <10.0 ng/mL
Study: 21115795
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral torezolid phosphate once daily for 5 to 7 days
Study: 21115795
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral torezolid phosphate once daily for 5 to 7 days
Study: 21115795
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral torezolid phosphate once daily for 5 to 7 days
Study: 21115795
Drug: Overall (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (all doses) for patients with S. aureus isolated at baseline
Study: 21115795
Drug: Overall (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (all doses) for patients with MRSA isolated at baseline
Study: 9878937
Drug: Weight-adjusted heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-adjusted heparin dosing
Study: 9878937
Drug: Weight-adjusted heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-adjusted heparin dosing and point-of-care monitoring
Study: 2104626
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (300 mg/week)
Study: 2104626
Drug: Placebo (sesame
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sesame oil, 1 mL)
Study: 102615
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and parenteral antibiotics with extensive bowel preparation in colorectal surgery
Study: 102615
Drug: Early preoperative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early preoperative administration of penicillinase-resistant drugs in open fractures (second and third degree lesions)
Study: 28615379
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNS-PL) containing 250 mug iodine, 20 g/d, 118 kcal
Study: 28615379
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid (IFA; 60 mg Fe/d + 400 mug folic acid/d)
Study: 26095867
Drug: Bridging therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging therapy with low‐molecular‐weight heparin (100 IU of dalteparin per kilogram of body weight) administered subcutaneously twice daily from 3 days before the procedure until 24 hours before the procedure and then for 5 to 10 days after the procedure.
Study: 26095867
Drug: No bridging
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bridging therapy (placebo).
Study: 26095867
Drug: Bridging therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging therapy with low‐molecular‐weight heparin (100 IU of dalteparin per kilogram of body weight).
Study: 11165220
Drug: Temporal covariance
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporal covariance method using Gd-chelates contrast agent during myocardial perfusion imaging.
Study: 2643592
Drug: Preoperative hyperthermia
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative hyperthermia (HT) 2 treatments per week
Study: 2643592
Drug: Preoperative hyperthermia
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative hyperthermia (HT) 1 treatment per week
Study: 78155
Drug: Probenecid 2
Normalized name: probenecid 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid 2 g given 30 min before 300 mg of rifampicin
Study: 78155
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg standard dose
Study: 24052026
Drug: Robotic‐assisted gait
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic‐assisted gait training plus conventional physical therapy
Study: 19929447
Drug: Eletriptan 40
Normalized name: eletriptan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eletriptan 40 mg and 80 mg
Study: 16971319
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% sildenafil applied twice daily for 3 months
Study: 15374558
Drug: Dolasetron 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 12.5 mg IV
Study: 15374558
Drug: Dolasetron 50
Normalized name: dolasetron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 50 mg IV
Study: 15374558
Drug: Dolasetron (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron (various doses)
Study: 11389118
Drug: Oral valaciclovir
Normalized name: valacyclovir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valaciclovir 1000 mg tds
Study: 11389118
Drug: Intravenous aciclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous aciclovir 5 mg/kg tds
Study: 8252687
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (colestipol 10 g TID plus niacin 1 g QID or lovastatin 20 mg BID)
Study: 8252687
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (placebos or colestipol if LDL cholesterol was elevated)
Study: 12616670
Drug: Delavirdine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delavirdine 400 mg tid with orange juice
Study: 12616670
Drug: Delavirdine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delavirdine 400 mg tid with water
Study: 2908819
Drug: Atenolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (beta 1-selective blocker without agonistic activity)
Study: 2908819
Drug: Visacor (ICI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visacor (ICI 141 292) (beta 1-selective blocker with moderate beta 1-selective agonism)
Study: 2908819
Drug: Corwin (ICI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corwin (ICI 118 587) (beta 1-selective blocker with high beta 1-selective agonism)
Study: 2908819
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three compounds during exercise-induced sympathetic activation
Study: 28512699
Drug: 60-mg edoxaban
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-mg edoxaban tablet crushed and administered via a nasogastric tube
Study: 28512699
Drug: 60-mg edoxaban
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-mg edoxaban tablet crushed and administered in apple puree
Study: 28512699
Drug: 60-mg edoxaban
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-mg edoxaban tablet (whole)
Study: 28512699
Drug: nasogastric tube
Normalized name: nasogastric tube
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasogastric tube suspension
Study: 24815673
Drug: ziprasidone (40-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: ziprasidone (40-160 mg/day)
Study: 12419717
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg and dexamethasone 8 mg (OD8 group)
Study: 12419717
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg and dexamethasone 16 mg (OD16 group)
Study: 12419717
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg (O group)
Study: 12419717
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg and dexamethasone 2 mg (OD2 group)
Study: 12419717
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg and dexamethasone 4 mg (OD4 group)
Study: 1683818
Drug: E100 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: E100 (100 mg esmolol)
Study: 1683818
Drug: E200 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: E200 (200 mg esmolol)
Study: 31288561
Drug: Insulin-dependent DM
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-dependent DM
Study: 25935943
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (paracetamol 500 mg + metoclopramide 10 mg + flunarizine 10 mg + alprazolam 0.5 mg)
Study: 19079814
Drug: TJ‐54 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ‐54 treatment (yokukansan) in period I
Study: 19079814
Drug: TJ‐54 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ‐54 treatment (yokukansan) in period II
Study: 19079814
Drug: TJ‐54 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ‐54 treatment in group A
Study: 19079814
Drug: TJ‐54 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ‐54 treatment in group B
Study: 19079814
Drug: TJ‐54 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ‐54 treatment
Study: 18085465
Drug: Olopatadine 0.2%
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine 0.2% ophthalmic solution (Pataday)
Study: 18085465
Drug: Olopatadine 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine 0.1% ophthalmic solution (Patanol)
Study: 16026692
Drug: Protracted venous
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protracted venous infusion (PVI) 5-FU for 12 weeks
Study: 11920308
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir for 8 weeks
Study: 10357377
Drug: Highly aggressive
Normalized name: Recombinant human highly phosphorylated acid alpha-glucosidase
DrugBank: Recombinant human highly phosphorylated acid alpha-glucosidase (DB17673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly aggressive antiretroviral therapy (HAART)
Study: 10357377
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination (ZDV, 3TC, SQV)
Study: 10357377
Drug: Quadruple combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple combination (ZDV, 3TC, SQV, RTV)
Study: 7573097
Drug: Interferon-α (IFN-α)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-α (IFN-α) therapy at a dosage of 5 million units (MU)/m2 per day
Study: 7573097
Drug: Interferon-α (IFN-α)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-α (IFN-α) therapy
Study: 7573097
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Interferon-α (IFN-α) and chemotherapy
Study: 2149493
Drug: Teicoplanin 6
Normalized name: teicoplanin 66.7 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 6 mg/kg
Study: 7381125
Drug: Metaproterenol 0.65
Normalized name: metaproterenol 0.65 mg/inh inhalation aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol 0.65 mg (3 inhalations at 10 and 20 min)
Study: 7381125
Drug: Metaproterenol 1.95
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol 1.95 mg (single inhalation)
Study: 21649633
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (FL, PSI, FL+PSI)
Study: 14555862
Drug: Rofecoxib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (25 mg cumulative dose: 6.25 mg + 18.75 mg 1 h later)
Study: 3885033
Drug: Penicillamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillamine (1 g per day)
Study: 30221864
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide treatment
Study: 24233343
Drug: HPV16 synthetic
Normalized name: Camphor (synthetic)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16 synthetic long-peptide vaccine (HPV16-SLP)
Study: 10388649
Drug: Vaccine formulated
Normalized name: hepatitis B vaccine, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine formulated into Iscom particles
Study: 10388649
Drug: Standard influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard influenza vaccine
Study: 1799472
Drug: Chlorambucil (CB;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (CB; 10 mg/day)
Study: 1799472
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with interferon alfa‐2b
Study: 29397092
Drug: Rhus capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhus capsules
Study: 27689547
Drug: Steroid +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid + antiviral
Study: 24152667
Drug: Home-based case
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based case management intervention (monthly home visits by nurses and physiotherapists for 12 months)
Study: 18033323
Drug: Etoposide, daunomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide, daunomycin (therapy likely to generate DNA double-strand breaks)
Study: 18033323
Drug: Anti-metabolite therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-metabolite therapy (fludarabine, cytarabine)
Study: 7731622
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulphate (i.v.)
Study: 6116296
Drug: Ketotifen 1
Normalized name: ketotifen 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 1 mg bd for four weeks
Study: 6116296
Drug: Ketotifen 1
Normalized name: ketotifen 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 1 mg, 2 mg, and 4 mg before exercise
Study: 28567691
Drug: Adipose tissue-derived
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose tissue-derived stem cells (ASCs) at a dose of 1 × 10^7 cells/mL
Study: 28567691
Drug: Adipose tissue-derived
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose tissue-derived stem cells (ASCs) at a dose of 2 × 10^7 cells/mL
Study: 26579572
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg in the morning) and placebo (in the evening) for 24 weeks
Study: 26579572
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg in the morning) and melatonin (5 mg in the evening) for 24 weeks
Study: 23713815
Drug: Rate control
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rate control strategy for treatment of AF
Study: 23713815
Drug: Rhythm control
Normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm control strategy for treatment of AF
Study: 21676011
Drug: XEN-D0501 1
Normalized name: XEN-D0501
DrugBank: XEN-D0501 (DB18673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN-D0501 1 mg twice daily
Study: 21676011
Drug: XEN-D0501 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN-D0501 2.5 mg twice daily
Study: 21676011
Drug: XEN-D0501 5
Normalized name: XEN-D0501
DrugBank: XEN-D0501 (DB18673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN-D0501 5 mg twice daily
Study: 21676011
Drug: XEN-D0501 5
Normalized name: XEN-D0501
DrugBank: XEN-D0501 (DB18673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN-D0501 5 mg single dose (fasted and fed conditions)
Study: 17205438
Drug: Single-dose azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose azithromycin (1 g)
Study: 17205438
Drug: 3-day azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day azithromycin (500 mg daily)
Study: 17205438
Drug: 3-day levofloxacin
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day levofloxacin (500 mg daily)
Study: 17205438
Drug: Azithromycin-based regimens
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin-based regimens (single-dose and 3-day)
Study: 15601351
Drug: 0.1% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% bupivacaine + 5 microg x ml(‐1) fentanyl
Study: 15601351
Drug: 0.0625% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625% bupivacaine + 5 microg x ml(‐1) fentanyl
Study: 9127169
Drug: Octreotide, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide, 40 micrograms/h, by continuous i.v. infusion for 5 days
Study: 9127169
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in addition to standard supportive therapy
Study: 1492864
Drug: 6-mg DHEC
Normalized name: DHEC
DrugBank: Dihydroergocristine (DB13345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mg DHEC oral vial once daily for 3 months
Study: 1492864
Drug: 6-mg DHEC
Normalized name: DHEC
DrugBank: Dihydroergocristine (DB13345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mg DHEC tablet once daily for 3 months
Study: 1492864
Drug: Placebo vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vial once daily for 3 months
Study: 1492864
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily for 3 months
Study: 31228760
Drug: AFS (fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFS (fentanyl bolus ± infusions)
Study: 31228760
Drug: PDS +
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDS + DSI (protocol-directed sedation + daily sedation interruption)
Study: 29197140
Drug: IFN-free treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-free treatment
Study: 26192385
Drug: Family-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioral treatment (FBT) for obesity
Study: 16496603
Drug: Non-diabetics after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-diabetics after administration of atropine (K-A)
Study: 11932840
Drug: Group analysis
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group analysis of evaluations (treatment questions)
Study: 10096582
Drug: Antiretroviral triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral triple combination therapy (after 1996)
Study: 10096582
Drug: Antiretroviral triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral triple combination therapy (before 1996)
Study: 8562300
Drug: Nefazodone hydrochloride
Normalized name: Nefazodone Hydrochloride
DrugBank: Nefazodone (DB01149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nefazodone hydrochloride 200 mg twice daily for 6 days
Study: 8562300
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg four times daily for 6 days
Study: 8562300
Drug: Nefazodone hydrochloride
Normalized name: Nefazodone Hydrochloride
DrugBank: Nefazodone (DB01149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nefazodone hydrochloride 200 mg twice daily + Cimetidine 300 mg four times daily for 6 days
Study: 2147630
Drug: 4 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 injections regimen (basal-prandial with short-acting insulin before meals and isophane (NPH) insulin at bedtime)
Study: 2147630
Drug: 5 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 injections regimen (4 injections plus a second injection of isophane (NPH) insulin before breakfast)
Study: 2147630
Drug: 4 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 injections regimen
Study: 2147630
Drug: 5 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 injections regimen
Study: 2147630
Drug: 4 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 injections regimen and 5 injections regimen
Study: 28289894
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (gallium‐aluminum‐arsenide diode laser, 20 mW, applied in five doses)
Study: 22116961
Drug: TIMA protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIMA protocol treatment by TIMA-trained psychiatrists over a 12-week period
Study: 22116961
Drug: TIMA protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIMA protocol treatment
Study: 21342376
Drug: Degarelix 80
Normalized name: degarelix 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix 80 mg monthly maintenance dose
Study: 18538469
Drug: Degarelix 160
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix 160 mg monthly maintenance dose
Study: 21342376
Drug: Leuprolide 7.5
Normalized name: leuprolide 7.5 mg/month intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide 7.5 mg monthly
Study: 15654489
Drug: Bethanecol chloride
Normalized name: Bethanechol Chloride
DrugBank: Bethanechol (DB01019)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bethanecol chloride tablets (20 mg, as needed)
Study: 9577354
Drug: Total Parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Parenteral Nutrition (TPN) for 7 days
Study: 7604754
Drug: Quinine sulphate
Normalized name: Quinine sulphate
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine sulphate capsule
Study: 7604754
Drug: Quinine dihydrochloride
Normalized name: quinine dihydrochloride
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine dihydrochloride plain tablet